SCHEMBL3637387

SCHEMBL3637387

Cc1cccc(C(C#N)N2CCN3CCC[C@@H]3C2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
ALDH1A1 P00352 4/20 0.46
POLB P06746 2/20 0.46
CHRM1 P11229 5/20 0.43
CHRM2 P08172 4/20 0.43
CHRM4 P08173 3/20 0.43
CHRM3 P20309 2/20 0.43
CHRM5 P08912 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 1/20 0.41
TSHR P16473 3/20 0.38
GAA P10253 1/20 0.38
MBTD1 Q05BQ5 1/20 0.37
L3MBTL3 Q96JM7 1/20 0.37
GHSR Q92847 1/20 0.36
ACHE P22303 2/20 0.36
SOS1 Q07889 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3746272 1.00 MEN1 (0.46) MEN1KMT2AALDH1A1POLBCHRM1
SCHEMBL3743336 0.79 GHSR (0.48) GHSR
SCHEMBL3636978 0.79 GHSR (0.48) GHSR
SCHEMBL3743771 0.78 KMT2A (0.43) MEN1KMT2AALDH1A1POLBCHRM1
SCHEMBL3637374 0.78 KMT2A (0.43) MEN1KMT2AALDH1A1POLBCHRM1
SCHEMBL3636129 0.77 GHSR (0.45) MEN1KMT2AALDH1A1POLBCHRM1
SCHEMBL3634477 0.75 MEN1 (0.43) MEN1KMT2AALDH1A1POLBCHRM1
SCHEMBL3739429 0.75 MEN1 (0.43) MEN1KMT2AALDH1A1POLBCHRM1
SCHEMBL13044885 0.75 CHRM2 (0.41) MEN1KMT2AALDH1A1POLBCHRM1
SCHEMBL3637111 0.74 TSHR (0.38) MEN1KMT2AALDH1A1POLBCHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
EP-2167466-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR Glaxo Group Limited (GB) 2010-03-31 EP disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GIPR, GHSR, GLP1R MEN1 3070/4885KMT2A 3646/4885ALDH1A1 2645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.